New data reveals that longer-term lebrikizumab treatment significantly improves outcomes for patients with moderate-to-severe atopic dermatitis who didn’t meet response criteria by week 16.
For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and ...